
SynAct Q2 2025 - Improved Cash and New PMR Programme

Redeye comments on SynAct Biopharma's Q2 report. After a directed share issue, loan agreement with Hunter Capital and HCM exercising warrants for SEK35m, SynAct is funded into 2027 and over the readout of its phase IIb study in RA and likely a potential license deal. The new funds also enable the company to start another investigator-sponsored trial, in polymyalgia rheumatica.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

SynAct Q2 2025 - Improved Cash and New PMR Programme